Expect significant downside at open — this Phase 3 failure removes a key label expansion catalyst for eplontersen and reduces Ionis' partnered pipeline value. The monotherapy subgroup signal (HR 0.71) provides some salvage value for the drug but is only nominally significant and will not support a regulatory filing. Monitor analyst revisions and partner AstraZeneca's response. The wider Ionis wholly owned portfolio and 2028 breakeven goal provide a floor, but near-term sentiment is clearly negative.
Price Chart
Executive Summary
Ionis announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM failed its primary endpoint of CV mortality and recurrent CV events vs placebo. The study enrolled 1,432 patients and missed statistical significance, likely eliminating eplontersen's ATTR-CM label expansion prospects, though a prespecified monotherapy subgroup showed a nominally significant HR of 0.71. Management attempted to soften the news by highlighting the wholly owned portfolio and 2028 cash flow breakeven target, but the pipeline setback is material.
Key Facts
- CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM failed to meet the primary composite endpoint of CV mortality and recurrent CV events vs placebo
- Study enrolled 1,432 participants, the largest ATTR-CM trial to date, across 130 sites in 20 countries
- 57% of patients in each arm received a stabilizer at baseline; 24% initiated a stabilizer during the trial
- Prespecified subgroup analysis of eplontersen monotherapy showed nominally significant HR of 0.71 on the primary composite
- No treatment effect observed in patients on baseline stabilizer therapy
- Multiple secondary imaging and biomarker analyses favored eplontersen; safety profile consistent with prior results
- WAINUA (eplontersen) is already approved for hATTR-PN in over 20 countries; ATTR-CM was the major expansion opportunity
- Ionis guided it remains on track to achieve cash flow breakeven by 2028
Financial Impact
The ATTR-CM indication represents a large commercial opportunity with an estimated 300,000 to 500,000 patients worldwide; failure of this Phase 3 likely eliminates that expansion, materially impairing eplontersen peak sales expectations and reducing the near-term value of Ionis' partnered asset
Risk Factors
- Potential for further pipeline de-rating if additional eplontersen trials are impacted
- Partner AstraZeneca may reduce commercialization commitments
- Full data readout at ESC Congress August 2026 could reveal additional negative signals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (IONS) — Batch item 1 | 0001140361-26-028092 |
| Document: ef20077664_ex99-1.htm | 0001140361-26-028092 |
| Document: 0001140361-26-028092-index-headers.html | 0001140361-26-028092 |
| Document: 0001140361-26-028092-index.html | 0001140361-26-028092 |
| Document: 0001140361-26-028092.txt | 0001140361-26-028092 |
| 8-K Filing (IONS) — Batch item 6 | 0001140361-26-028092 |
| Document: ef20077664_ex99-1.htm | 0001140361-26-028092 |
| Document: 0001140361-26-028092-index-headers.html | 0001140361-26-028092 |
| Document: 0001140361-26-028092-index.html | 0001140361-26-028092 |
| Document: 0001140361-26-028092.txt | 0001140361-26-028092 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $42.93 | awaiting T+20 | — | $43.96 (+2.40%) |
Oct 21, 2026 6d ago | 8-K | $43.91 | awaiting T+20 | — | $43.96 (+0.11%) |
Oct 21, 2026 6d ago | Institutional Cluster | $43.91 | awaiting T+20 | — | $43.96 (+0.11%) |
Sep 23, 2026 4w ago | 8-K | $43.93 $44.27 | ▲ +0.77% | ▲ +0.09% | $43.96 (+0.07%) |
Sep 4, 2026 7w ago | 8-K | $56.71 $44.00 | ▲ +22.41% | ▲ +24.13% | $43.96 (+22.48%) |
Sep 4, 2026 7w ago | 8-K | $58.09 $43.50 | ▼ −25.12% | ▼ −25.72% | $43.96 (−24.32%) |
Jul 31, 2026 12w ago | Insider Buy | $54.49 $60.36 | ▲ +10.77% | ▲ +9.53% | $43.96 (−19.32%) |
Jul 29, 2026 12w ago | 8-K | $54.04 $63.36 | ▲ +17.25% | ▲ +12.23% | $43.96 (−18.65%) |
Jul 9, 2026 15w ago | 8-K | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.96 (−24.53%) |
Jul 9, 2026 15w ago | Insider Cluster | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.96 (−24.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers